Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Atrial Fibrillation | 9 | 2019 | 2320 | 1.74 | Why? |
| Carcinoma, Renal Cell | 6 | 2019 | 545 | 1.34 | Why? |
| Kidney Neoplasms | 5 | 2019 | 832 | 1.09 | Why? |
| Down Syndrome | 2 | 2017 | 397 | 0.98 | Why? |
| Pneumonia, Staphylococcal | 1 | 2021 | 38 | 0.91 | Why? |
| Private Sector | 1 | 2021 | 262 | 0.75 | Why? |
| Femur Neck | 1 | 2017 | 29 | 0.72 | Why? |
| Emergency Services, Psychiatric | 1 | 2021 | 175 | 0.70 | Why? |
| Bone Diseases, Metabolic | 1 | 2017 | 64 | 0.67 | Why? |
| Government Programs | 1 | 2021 | 512 | 0.65 | Why? |
| Gastrointestinal Stromal Tumors | 1 | 2017 | 84 | 0.64 | Why? |
| Lumbar Vertebrae | 1 | 2017 | 196 | 0.61 | Why? |
| Anticoagulants | 6 | 2019 | 9563 | 0.59 | Why? |
| Arthroplasty, Replacement, Knee | 2 | 2018 | 363 | 0.59 | Why? |
| Vaccinia virus | 1 | 2017 | 346 | 0.57 | Why? |
| Psychosocial Support Systems | 1 | 2021 | 710 | 0.57 | Why? |
| Unemployment | 1 | 2021 | 702 | 0.56 | Why? |
| Urogenital Neoplasms | 1 | 2017 | 177 | 0.55 | Why? |
| Imatinib Mesylate | 1 | 2017 | 327 | 0.55 | Why? |
| Bone Density | 1 | 2017 | 335 | 0.55 | Why? |
| Virus Assembly | 1 | 2017 | 438 | 0.54 | Why? |
| Patient Readmission | 2 | 2021 | 1543 | 0.48 | Why? |
| Gastrointestinal Neoplasms | 1 | 2017 | 392 | 0.47 | Why? |
| Telephone | 1 | 2021 | 1705 | 0.46 | Why? |
| Osteoporosis | 1 | 2017 | 410 | 0.46 | Why? |
| Staphylococcal Infections | 1 | 2021 | 1099 | 0.45 | Why? |
| Antineoplastic Agents | 3 | 2017 | 3550 | 0.45 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.44 | Why? |
| Fibrinolytic Agents | 2 | 2018 | 1702 | 0.40 | Why? |
| Employment | 1 | 2021 | 1754 | 0.40 | Why? |
| Protein Kinase Inhibitors | 1 | 2017 | 1585 | 0.33 | Why? |
| Frailty | 1 | 2019 | 1432 | 0.33 | Why? |
| Anesthesia | 1 | 2017 | 1236 | 0.33 | Why? |
| Patient Discharge | 3 | 2021 | 5696 | 0.32 | Why? |
| Remote Consultation | 1 | 2021 | 2396 | 0.31 | Why? |
| Thrombophilia | 1 | 2018 | 1935 | 0.30 | Why? |
| Vitamin K | 2 | 2018 | 263 | 0.29 | Why? |
| Spain | 9 | 2021 | 15545 | 0.28 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.27 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.27 | Why? |
| Biomarkers, Tumor | 3 | 2017 | 1314 | 0.26 | Why? |
| Latent Tuberculosis | 2 | 2018 | 324 | 0.26 | Why? |
| Pneumonia | 2 | 2021 | 5652 | 0.26 | Why? |
| Administration, Oral | 3 | 2018 | 2340 | 0.24 | Why? |
| Medical Oncology | 1 | 2019 | 3826 | 0.24 | Why? |
| Acute Kidney Injury | 2 | 2018 | 5762 | 0.22 | Why? |
| Proto-Oncogene Proteins c-kit | 2 | 2017 | 59 | 0.21 | Why? |
| Stroke | 4 | 2018 | 8839 | 0.21 | Why? |
| Mentally Ill Persons | 1 | 2021 | 103 | 0.19 | Why? |
| Radium | 1 | 2018 | 7 | 0.19 | Why? |
| DNA Repair | 1 | 2019 | 114 | 0.19 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.18 | Why? |
| Microscopy, Electron, Scanning Transmission | 1 | 2017 | 2 | 0.18 | Why? |
| Poxviridae | 1 | 2017 | 23 | 0.18 | Why? |
| Neoplastic Cells, Circulating | 1 | 2018 | 68 | 0.18 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2018 | 2483 | 0.18 | Why? |
| Pain Threshold | 1 | 2017 | 46 | 0.18 | Why? |
| Anilides | 1 | 2018 | 105 | 0.18 | Why? |
| Arthritis, Infectious | 1 | 2019 | 111 | 0.17 | Why? |
| Skin Tests | 1 | 2018 | 229 | 0.17 | Why? |
| Analysis of Variance | 2 | 2018 | 950 | 0.17 | Why? |
| Hemorrhage | 3 | 2018 | 3013 | 0.17 | Why? |
| Aged, 80 and over | 15 | 2021 | 88759 | 0.17 | Why? |
| Electron Microscope Tomography | 1 | 2017 | 167 | 0.17 | Why? |
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 109 | 0.17 | Why? |
| Absorptiometry, Photon | 1 | 2017 | 168 | 0.17 | Why? |
| Pyrroles | 2 | 2017 | 292 | 0.17 | Why? |
| Delphi Technique | 2 | 2019 | 1257 | 0.16 | Why? |
| Bevacizumab | 1 | 2018 | 149 | 0.16 | Why? |
| Drug Resistance, Neoplasm | 2 | 2017 | 447 | 0.16 | Why? |
| Cyclooxygenase 2 | 1 | 2017 | 129 | 0.16 | Why? |
| Tuberculin Test | 1 | 2017 | 141 | 0.16 | Why? |
| Everolimus | 1 | 2018 | 215 | 0.16 | Why? |
| Practice Guidelines as Topic | 2 | 2017 | 15421 | 0.16 | Why? |
| Hospitals, Veterans | 1 | 2018 | 229 | 0.16 | Why? |
| International Normalized Ratio | 1 | 2018 | 300 | 0.16 | Why? |
| Prostatic Neoplasms | 2 | 2019 | 1637 | 0.15 | Why? |
| Logistic Models | 4 | 2018 | 9089 | 0.15 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.15 | Why? |
| Humans | 40 | 2021 | 930598 | 0.15 | Why? |
| Knee Joint | 1 | 2017 | 194 | 0.15 | Why? |
| Mercaptopurine | 1 | 2015 | 68 | 0.15 | Why? |
| Electric Countershock | 1 | 2018 | 284 | 0.15 | Why? |
| Prosthesis-Related Infections | 1 | 2019 | 302 | 0.15 | Why? |
| Age Factors | 5 | 2021 | 21039 | 0.14 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.14 | Why? |
| Hospital Mortality | 2 | 2018 | 22087 | 0.14 | Why? |
| Bone Neoplasms | 1 | 2018 | 287 | 0.14 | Why? |
| Azathioprine | 1 | 2015 | 161 | 0.14 | Why? |
| Staphylococcus aureus | 1 | 2021 | 844 | 0.14 | Why? |
| Androgen Antagonists | 1 | 2018 | 404 | 0.14 | Why? |
| Spondylarthritis | 1 | 2017 | 174 | 0.14 | Why? |
| Angiogenesis Inhibitors | 1 | 2018 | 395 | 0.14 | Why? |
| Multivariate Analysis | 4 | 2018 | 5440 | 0.14 | Why? |
| Program Development | 1 | 2021 | 1089 | 0.14 | Why? |
| Endoplasmic Reticulum | 1 | 2017 | 430 | 0.14 | Why? |
| Mental Health | 1 | 2021 | 15770 | 0.14 | Why? |
| Gastrointestinal Agents | 1 | 2018 | 393 | 0.13 | Why? |
| Viremia | 1 | 2021 | 1020 | 0.13 | Why? |
| Syndrome | 1 | 2019 | 1310 | 0.13 | Why? |
| Heart Valve Diseases | 1 | 2018 | 355 | 0.13 | Why? |
| Warfarin | 1 | 2018 | 402 | 0.13 | Why? |
| Disease-Free Survival | 4 | 2020 | 1654 | 0.13 | Why? |
| Secondary Prevention | 1 | 2018 | 762 | 0.12 | Why? |
| Geriatric Assessment | 2 | 2018 | 1372 | 0.12 | Why? |
| Life Expectancy | 1 | 2017 | 474 | 0.12 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.12 | Why? |
| Withholding Treatment | 1 | 2018 | 798 | 0.12 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.11 | Why? |
| Government | 1 | 2021 | 1453 | 0.11 | Why? |
| Aged | 16 | 2021 | 215776 | 0.11 | Why? |
| Indoles | 2 | 2017 | 1243 | 0.11 | Why? |
| Adenocarcinoma | 1 | 2018 | 651 | 0.11 | Why? |
| Registries | 3 | 2021 | 12327 | 0.11 | Why? |
| Myocardial Ischemia | 1 | 2018 | 781 | 0.11 | Why? |
| Delivery of Health Care | 1 | 2017 | 15909 | 0.11 | Why? |
| Male | 23 | 2021 | 367725 | 0.11 | Why? |
| Meta-Analysis as Topic | 1 | 2018 | 1289 | 0.11 | Why? |
| Multicenter Studies as Topic | 1 | 2018 | 2437 | 0.11 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.11 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.11 | Why? |
| Arthritis, Psoriatic | 1 | 2017 | 625 | 0.11 | Why? |
| Hyperglycemia | 1 | 2021 | 1363 | 0.11 | Why? |
| Organizational Innovation | 1 | 2021 | 2468 | 0.11 | Why? |
| Inflammatory Bowel Diseases | 2 | 2018 | 3209 | 0.10 | Why? |
| Civil Defense | 1 | 2021 | 1687 | 0.09 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 9335 | 0.09 | Why? |
| Seroconversion | 1 | 2018 | 2515 | 0.09 | Why? |
| Female | 19 | 2021 | 380317 | 0.09 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.09 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1573 | 0.09 | Why? |
| Veterans | 1 | 2018 | 1131 | 0.09 | Why? |
| Personal Satisfaction | 1 | 2017 | 1243 | 0.08 | Why? |
| Prostate-Specific Antigen | 2 | 2018 | 213 | 0.08 | Why? |
| Radiotherapy Dosage | 2 | 2018 | 428 | 0.08 | Why? |
| Crohn Disease | 1 | 2015 | 959 | 0.08 | Why? |
| Blood Coagulation | 1 | 2019 | 2768 | 0.08 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.07 | Why? |
| Risk Assessment | 3 | 2018 | 25439 | 0.07 | Why? |
| Mutation | 4 | 2019 | 12376 | 0.07 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.07 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.07 | Why? |
| Prospective Studies | 6 | 2018 | 43301 | 0.07 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.07 | Why? |
| Length of Stay | 2 | 2021 | 11042 | 0.07 | Why? |
| Consensus | 1 | 2019 | 6345 | 0.07 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.07 | Why? |
| Electrocardiography | 1 | 2018 | 3957 | 0.07 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.07 | Why? |
| Kaplan-Meier Estimate | 3 | 2018 | 4260 | 0.06 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.06 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.06 | Why? |
| Cross-Sectional Studies | 4 | 2018 | 53120 | 0.06 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.06 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.06 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.06 | Why? |
| Clinical Trials as Topic | 2 | 2018 | 7330 | 0.06 | Why? |
| Aging | 1 | 2017 | 3581 | 0.05 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.05 | Why? |
| Prognosis | 3 | 2018 | 32490 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.05 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.05 | Why? |
| Adult | 9 | 2021 | 244371 | 0.05 | Why? |
| Young Adult | 3 | 2021 | 93724 | 0.05 | Why? |
| Platinum | 1 | 2019 | 54 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Gonadotropin-Releasing Hormone | 1 | 2018 | 53 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Indazoles | 1 | 2018 | 77 | 0.05 | Why? |
| Cell Count | 1 | 2018 | 228 | 0.04 | Why? |
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 121 | 0.04 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.04 | Why? |
| Animals | 2 | 2017 | 78931 | 0.04 | Why? |
| Injections, Intravenous | 1 | 2018 | 381 | 0.04 | Why? |
| ras Proteins | 1 | 2016 | 37 | 0.04 | Why? |
| Neoplasm Grading | 1 | 2018 | 400 | 0.04 | Why? |
| Mesalamine | 1 | 2017 | 89 | 0.04 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.04 | Why? |
| Receptors, Androgen | 1 | 2019 | 212 | 0.04 | Why? |
| Comorbidity | 2 | 2018 | 34796 | 0.04 | Why? |
| Comparative Effectiveness Research | 1 | 2017 | 178 | 0.04 | Why? |
| Clinical Studies as Topic | 1 | 2016 | 118 | 0.04 | Why? |
| Biomedical Research | 1 | 2016 | 5270 | 0.04 | Why? |
| Surveys and Questionnaires | 2 | 2021 | 43792 | 0.04 | Why? |
| Prostate | 1 | 2018 | 283 | 0.04 | Why? |
| Gene Expression Profiling | 2 | 2018 | 3788 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 179 | 0.04 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 243 | 0.04 | Why? |
| Receptor, ErbB-2 | 1 | 2016 | 267 | 0.04 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.04 | Why? |
| Polypharmacy | 1 | 2018 | 347 | 0.04 | Why? |
| Adalimumab | 1 | 2018 | 389 | 0.03 | Why? |
| ErbB Receptors | 1 | 2016 | 320 | 0.03 | Why? |
| Immunosuppressive Agents | 3 | 2018 | 6331 | 0.03 | Why? |
| Models, Genetic | 1 | 2017 | 434 | 0.03 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.03 | Why? |
| Infliximab | 1 | 2018 | 502 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Treatment Outcome | 5 | 2018 | 51732 | 0.03 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.03 | Why? |
| Laparotomy | 1 | 2015 | 241 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Colectomy | 1 | 2015 | 327 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2015 | 1008 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.03 | Why? |
| Gene Frequency | 1 | 2017 | 1210 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1014 | 0.03 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.03 | Why? |
| Steroids | 1 | 2017 | 904 | 0.03 | Why? |
| Checklist | 1 | 2017 | 714 | 0.03 | Why? |
| United States | 1 | 2018 | 46150 | 0.03 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.03 | Why? |
| Adolescent | 1 | 2021 | 86841 | 0.03 | Why? |
| Pyrimidines | 1 | 2018 | 1557 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2017 | 1999 | 0.02 | Why? |
| Sulfonamides | 1 | 2018 | 1294 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Precision Medicine | 1 | 2019 | 1477 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.02 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.02 | Why? |
| Blood Glucose | 1 | 2021 | 3642 | 0.02 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.02 | Why? |
| Rheumatology | 1 | 2017 | 1213 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2015 | 3776 | 0.02 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2019 | 9893 | 0.02 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2018 | 6537 | 0.01 | Why? |
| Databases, Factual | 1 | 2015 | 6248 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2019 | 10083 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2021 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2021 | 253789 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2015 | 48226 | 0.01 | Why? |
| Pandemics | 1 | 2021 | 389249 | 0.00 | Why? |
Suárez Fernández's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(251)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(159)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_